<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8748</journal-id>
<journal-title><![CDATA[Acta Neurológica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Neurol Colomb.]]></abbrev-journal-title>
<issn>0120-8748</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87482020000300047</article-id>
<article-id pub-id-type="doi">10.22379/24224022293</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Recomendaciones para el manejo de los pacientes con enfermedades neuromusculares en el contexto de la pandemia covid-19]]></article-title>
<article-title xml:lang="en"><![CDATA[Recommendations for the treatment of patients with neuromuscular disorders in the context of the COVID-19 pandemic]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Millán Pérez]]></surname>
<given-names><![CDATA[Sonia Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fontanilla Díaz]]></surname>
<given-names><![CDATA[Luis Alejandro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marentes Cubillos]]></surname>
<given-names><![CDATA[Alba Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario San Ignacio  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Clínica San Rafael  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central de la policía  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<fpage>47</fpage>
<lpage>53</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87482020000300047&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87482020000300047&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87482020000300047&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Los trastornos neuromusculares, constituyen un grupo heterogéneo de padecimientos crónicos, genéticos o de origen inmunológico que afectan a todos los grupos etarios. Muchos de los pacientes afectados, cursan con debilidad muscular, trastornos respiratorios, cardiovasculares y algunos de ellos requieren del uso de medicamentos inmunosupresores o terapias de infusión en el ámbito hospitalario. En la actualidad, el mundo se enfrenta a la pandemia generada por la enfermedad por Coronavirus 2019, (Coronavirus Disease 2019, covid-19), que es la entidad causada por la infección por el Coronavirus del Síndrome-Respiratorio Agudo Severo o Grave 2 (severe respiratory acute syndrome 2, SARS-CoV-2). En esta patología, se han descrito factores de mal pronóstico entre los que se encuentran edad mayor de 60 años, comorbilidades como diabetes mellitus, enfermedad pulmonar, enfermedad cardiovascular, hipertensión arterial, cáncer e inmunosupresión. Teniendo en cuenta lo anterior, surge la necesidad de establecer unas recomendaciones generales para el cuidado de los pacientes con patologías neuromusculares durante la pandemia, basadas en la literatura disponible que permitan una orientación inicial en el manejo de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY Neuromuscular disorders constitute a heterogeneous group of chronic, genetic or immunological disorders that affect all age groups. Many of the affected patients have muscle weakness, respiratory and cardiovascular disorders, and some of them require the use of immunosuppressive drugs or infusion therapies in the hospital setting. Currently, the world is facing the pandemic caused by Coronavirus Disease 2019, (Coronavirus Disease 2019, COVID-19), which is the entity caused by infection by the severe respiratory acute syndrome 2, SARS-CoV-2). In this pathology, factors of poor prognosis have been described, among which are age over 60 years, comorbidities such as diabetes mellitus, lung disease, cardiovascular disease, high blood pressure, cancer and immunosuppression. Taking into account the aforementioned, the need arises to establish general recommendations for the care of patients with neuromuscular pathologies during the pandemic, based on the available literature that allows initial orientation in the management of patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[covid-19]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades neuromusculares]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[Neurofisiologia (DeCS)]]></kwd>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[Neuromuscular Disorders]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[Neurophysiology (MeSH)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saavedra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-CoV-2/ Covid-19 en establecimientos de atención de la salud Recomendaciones basadas en consenso de expertos e informadas en la evidencia]]></article-title>
<collab>Grupo ACIN- IETS de Consenso Colombiano para recomendaciones de atención COVID19</collab>
<source><![CDATA[Infectio]]></source>
<year>2020</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-153</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacob]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Muppidi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Guidon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Guptill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hehir]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International MG/COVID-19 Working Group, Guidance for the management of myasthenia gravis (MG) and Lambert - Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2020</year>
<volume>412</volume>
<page-range>116803</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gulati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pomeranz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Qamar]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Frisch]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comprehensive review of manifestations of novel coronaviruses in the context of deadly COVID-19 global pandemic]]></article-title>
<source><![CDATA[Am J Med Sci]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taki]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Gahlot]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dhangar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment]]></article-title>
<source><![CDATA[Sci Total Environ]]></source>
<year>2020</year>
<volume>734</volume>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Tu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study]]></article-title>
<source><![CDATA[Am J Respir Crit Care Med]]></source>
<year>2020</year>
<volume>201</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1372-9</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solé]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sarlort-Campana]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pereon]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Stojkovic]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wahbi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Cintas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network]]></article-title>
<source><![CDATA[Revue neurologique]]></source>
<year>2020</year>
<volume>176</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>507-15</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Public Health, England</collab>
<source><![CDATA[Guidance on shielding and protecting people who are clinically extremely vulnerable from COVID-19]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lizarazo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Picón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carreño]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Orientaciones de medidas preventivas y de mitigación para contener la infección respiratoria aguda por COVID-19, dirigidas a la población en general]]></source>
<year></year>
<publisher-name><![CDATA[Ministerio de salud y protección social Bogotá, marzo de 2020. Gestión de las intervenciones individuales y colectivas para la promoción de la salud y prevención de la enfermedad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wechsler]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advantages and limitations of teleneurology]]></article-title>
<source><![CDATA[JAMA Neurol]]></source>
<year>2015</year>
<volume>72</volume>
<page-range>349-54</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallegos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Telesalud y telemedicina para la prestación de servicios de salud en la pandemia por Covid-19 GESTION DE PRESTACIÓN DE SERVICIOS EN SALUD]]></source>
<year>2020</year>
<publisher-name><![CDATA[Ministerio de Salud y Protección Social Bogotá]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finkel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Chiriboga]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Vajsar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Day]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Vivo]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose escalation study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<page-range>3017-26</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hundsberger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rósler]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Findling]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2014</year>
<volume>261</volume>
<page-range>1684-90</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scheidegger]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Leupold]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sauter]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Findling]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rósler]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Hundsberger]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[36-months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>2018</year>
<volume>265</volume>
<page-range>2783-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez-Duarte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[O'Riordan]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[C-C]]></given-names>
</name>
<name>
<surname><![CDATA[Ueda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kristen]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2018</year>
<volume>379</volume>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gautret]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lagier]]></surname>
<given-names><![CDATA[J-C]]></given-names>
</name>
<name>
<surname><![CDATA[Parola]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hoang]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
<name>
<surname><![CDATA[Meddeb]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mailhe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2020</year>
<volume>105949</volume>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bouadma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morawiec]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Maury]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Constantin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Montravers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Recommandations d'experts portant sur la prise en charge en réanimation des patients en période d'épidémie a SARS-CoV2. 2020. Recommandations-dexperts-COVID-9-mars-2020.pdf]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hui]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tsang]]></surname>
<given-names><![CDATA[OTY]]></given-names>
</name>
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks]]></article-title>
<source><![CDATA[Eur RespirJ]]></source>
<year>2019</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1802339</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[San-Juan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Jiménez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ximénez Camilli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[De La Cruz Reyes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre Galindo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Burbano]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidance for clinical neurophysiology examination throughout the COVID-19 pandemic. Latin American chapter of the IFCN task force - COVID-19]]></article-title>
<source><![CDATA[Clin Neurophysiol]]></source>
<year>2020</year>
<volume>131</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1589-98</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kassardjian]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Narayanaswami]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[AANEM Quality and Patient Safety Committee of the AANEM. Practical Guidance for Managing EMG Requests and Testing during the COVID-19 Pandemic. Muscle Nerve]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
